RBC Capital analyst Brian Abrahams lowered his price target on Sarepta to $164, acknowledging that the company's dynamics have been complicated by the FDA requirement of an additional "confirmatory study" for microdystrophin approval and the disappointment from the "lack of limb girdle data at a recent investor conference". The analyst keeps his Outperform rating on the shares however, noting that he is maintaining his confidence in the $5B total potential of its muscular dystrophy gene therapy programs. Abrahams also views Sarepta as a "potential M&A target given its solid PMO franchise revenue foundation" along with its "accelerating gene therapy development / manufacturing expertise."